“Patients and physicians have a new treatment option with BREO ELLIPTA, the first once-daily ICS/LABA for the maintenance treatment of COPD,” said Jorge Bartolome, senior vice president of GSK Respiratory Business Unit in the U.S. “This new option for healthcare providers to prescribe is good news for the millions of people in the U.S. affected by COPD.” - See more at: http://www.rtmagazine.com/2013/10/copd-treatment-breo-ellipta-now-available-in-u-s/#sthash.KG8ni9ni.dpuf